OPAL BAKER: Open Payments
NPI 1346904026 · BRONX, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,283 in 16 payments from 10 companies in 2025. Trend: 2023 $128 · 2024 $165 · 2025 $1,283
Food & beverage: $1,283
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $378 |
| Astellas Pharma US Inc | 3 | $159 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $148 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Incyte Corporation | 1 | $124 |
| GlaxoSmithKline, LLC. | 1 | $118 |
| PharmaEssentia USA Corporation | 1 | $116 |
| AstraZeneca Pharmaceuticals LP | 2 | $54 |
| Rigel Pharmaceuticals, Inc. | 1 | $43 |
| Merck Sharp & Dohme LLC | 1 | $18 |
Products named: RYBREVANT, INJECTAFER, Padcev, Monjuvi, OJJAARA, BESREMI, TAVALISSE, Vyloy.
Industry payments across NY — which companies pay providers there.
